Citalopram

Selective Serotonin Reuptake Inhibitor (SSRI)

Drug Overview

Citalopram, marketed under the brand names Celexa, Cipralex, and Lexapro, is a prescription antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class.

It is primarily used to treat major depressive disorder and various anxiety disorders. By blocking the serotonin transporter, citalopram increases serotonin levels in the brain to help improve mood and reduce anxiety symptoms.

The drug is metabolized in the liver by enzymes including CYP2C19 into less active metabolites, which are then excreted by the kidneys.

Relevant Genes and Their Roles

CYP2C19 is the key enzyme responsible for converting citalopram into its primary inactive metabolite, desmethylcitalopram. Genetic variants in the CYP2C19 gene can speed up or slow down this process.

These variants categorize individuals into metabolizer groups—ultrarapid, rapid, normal, intermediate, and poor—based on how effectively their CYP2C19 enzyme functions. Faster metabolism lowers drug levels, while slower metabolism raises levels, affecting both efficacy and side effect risk.

Impact of Genetics on Drug Response

Patients with ultrarapid or rapid CYP2C19 phenotypes may clear citalopram too quickly, leading to reduced drug exposure and diminished clinical benefit. Conversely, intermediate or poor metabolizers may have elevated plasma concentrations, increasing the likelihood of side effects such as QT prolongation. Normal metabolizers are expected to achieve standard therapeutic levels and response.

Expected Clinical Effects of Genetic Variation

Ultrarapid Metabolizer

  • Effect on drug levels: Significantly decreased plasma concentrations.
  • Clinical consequence: Reduced likelihood of therapeutic benefit.
  • Side effects: Lower risk of common SSRI side effects; typically mild when present.

Rapid Metabolizer

  • Effect on drug levels: Decreased plasma concentrations.
  • Clinical consequence: Possible reduced efficacy requiring dose adjustment.
  • Side effects: Slightly lower frequency of side effects; generally mild.

Normal Metabolizer

  • Effect on drug levels: Expected therapeutic plasma concentrations.
  • Clinical consequence: Standard therapeutic response.
  • Side effects: Typical SSRI side effect profile; mild to moderate frequency.

Intermediate Metabolizer

  • Effect on drug levels: Increased plasma concentrations.
  • Clinical consequence: Heightened risk of dose-related side effects.
  • Side effects: Moderate severity (e.g., nausea, headache); may occur more frequently.

Poor Metabolizer

  • Effect on drug levels: Substantially increased plasma concentrations.
  • Clinical consequence: Increased risk of adverse reactions and toxicity (e.g., QT prolongation).
  • Side effects: Severe or more frequent side effects such as dizziness and cardiac conduction changes.

Indeterminate/Not Available

  • Effect on drug levels: Unknown.
  • Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
  • Side effects: Unknown; monitor patient accordingly.

Dosing Guidelines

The following dosing guidelines are based on CPIC recommendations for citalopram and the CYP2C19 genotype.

CYP2C19 Dosing Guideline

Phenotype Clinical Consequence Guideline Recommendation
Ultrarapid Metabolizer Lower plasma concentrations; reduced efficacy. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used and efficacy is insufficient, titrate to a higher maintenance dose.
Rapid Metabolizer Lower plasma concentrations; reduced efficacy. Initiate therapy at the recommended starting dose. If response is inadequate, consider titrating to a higher maintenance dose or switching to an alternative antidepressant not predominantly metabolized by CYP2C19.
Normal Metabolizer Normal metabolism; expected therapeutic response. Initiate therapy with the recommended starting dose.
Intermediate Metabolizer Higher plasma concentrations; increased side effect risk. Initiate therapy with the recommended starting dose. Consider a slower titration schedule and lower maintenance dose than for normal metabolizers.
Likely Intermediate Metabolizer Higher plasma concentrations; increased side effect risk. Initiate therapy with the recommended starting dose. Consider a slower titration schedule and lower maintenance dose than for normal metabolizers.
Likely Poor Metabolizer Higher plasma concentrations; increased side effect risk. Consider an alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used, start at a lower dose, use slower titration, and reduce standard maintenance dose by 50%.
Poor Metabolizer Higher plasma concentrations; increased side effect risk. Consider an alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used, start at a lower dose, use slower titration, and reduce standard maintenance dose by 50%.
Indeterminate/Not Available Unknown impact. Initiate therapy with the recommended starting dose.

Alternative Treatment Options

The CPIC guideline suggests considering antidepressants not predominantly metabolized by CYP2C19, such as sertraline or paroxetine, as alternative treatment options. Other classes like SNRIs (e.g., venlafaxine) may also be considered depending on clinical context. These are examples only and not a substitute for professional medical advice.

Sources and References

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested